Vorsorge und Nachsorge beim Ovarialkarzinom

Zusammenfassung

Ovarial-, Tuben- und primäres Peritonealkarzinom werden in ca. 70 % der Fälle erst in fortgeschrittenem Stadium erkannt. Trotz bemerkenswerter Erfolge der Erstlinientherapie (zytoreduktive Operation, Platin-haltige Chemotherapie) mit vielfach dem Erreichen kompletter Remissionen erleiden dennoch mehr als 70 % der Patientinnen mit fortgeschrittenem Karzinom ein Rezidiv. Die Prognose eines frühen Tumorstadiums ist besser. Frühe Diagnostik und adäquate Nachsorge könnten dazu beitragen, den Verlauf einer Ovarial-, Tuben- oder primären Peritonealkarzinomerkrankung günstig zu beeinflussen.

Summary

Ovarian cancer, cancer of the fallopian tube and primary peritoneal carcinoma are most often diagnosed at an advanced disease stage. Despite remarkable success of first line therapy including cytoreductive surgery and platinum containing chemotherapy, more than 70 % of patients with advanced disease will suffer from relapse. Early stage ovarian cancer is characterized by better prognosis. Early diagnosis and appropriate follow up might potentially contribute to a better course of disease.

Ovarialkarzinom - Vorsorge - Nachsorge - Screening

Ovarian carcinoma - diagnosis - after-care - screening

Literatur

• 01 American Cancer Society .„Cancer Facts and Figures 2003.” 2003 http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf
• 02 Bermejo-Perez M J, Marquez-Calderon S et al.. Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review.  Br J Radiol. 2008;  81 (963) 172-9
• 03 du Bois A, Quinn M et al.. Consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).  Ann Oncol. 2005;  16 Suppl 8: viii7–viii12
• 04 Edwards B K, Brown M L, Wingo P A et al.. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment.  J Natl Cancer Inst. 2005;  97 (19) 1407-27
• 05 Einhorn N, Sjovall K et al.. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer.  Obstet Gynecol. 1992;  80 (1) 14-8
• 06 Gondos A, Holleczek B et al.. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients?.  Ann Oncol. 2007;  18 (7) 1253-9
• 07 Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.  J Clin Oncol. 2004;  22 (7) 1315-27
• 08 Kommission Ovar der Arbeitsgemeinschaft Gynäkologische Onkologie e. V . S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. Stand September 2010. 2010 http://www.ago-online.de/index.php?lang=de&site=ovar_guide_ topical&topic=ovar_guide
• 09 Lux M, Fasching P A et al.. Hereditary breast and ovarian cancer: review and future perspectives.  J Mol Med. 2006;  84 (1) 16-28
• 10 Miller R E, Rustin G J. How to follow-up patients with epithelial ovarian cancer.  Curr Opin Oncol. 2010;  22 (5) 498-502
• 11 Ries L A. Ovarian cancer. Survival and treatment differences by age.  Cancer. 1993;  71 (2 Suppl) 524-9
• 12 Risch H A, McLaughlin J R et al.. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.  Am J Hum Genet. 2001;  68 (3) 700-10
• 13 Rosenthal A N, Menon U et al.. Screening for ovarian cancer.  Clin Obstet Gynecol. 2006;  49 (3) 433-47
• 14 Rustin G J, van der Burg M E, Griffin C L et al.. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.  Lancet. 2010;  376 (9747) 1155-63
• 15 Schmalfeldt B, du Bois A et al.. Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO.  Zentralbl Gynakol. 2006;  128 (1) 11-7
• 16 Schorge J O, Modesitt S C, Coleman R L et al.. SGO White Paper on ovarian cancer: etiology, screening and surveillance.  Gynecol Oncol. 2010;  119 (1) 7-17
• 17 Stevens E V, Liotta L A et al.. Proteomic analysis for early detection of ovarian cancer: a realistic approach?.  Int J Gynecol Cancer. 2003;  13 Suppl 2 133-9
• 18 Tanner E J, Chi D S, Eisenhauer E L et al.. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?.  Gynecol Oncol. 2010;  117 (2) 336-40
• 19 Thompson D, Easton D F. Cancer Incidence in BRCA1 mutation carriers.  J Natl Cancer Inst. 2002;  94 (18) 1358-65
• 20 Trimble E L, Karlan B Y et al.. Diagnosing the correct ovarian cancer syndrome.  Obstet Gynecol. 1991;  78 (6) 1023-6
• 21 van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynaecologic cancers.  Curr Opin Obstet Gynecol. 2011;  23 (1) 3-7
• 22 van Haaften-Day C, Shen Y et al.. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.  Cancer. 2001;  92 (11) 2837-44
• 23 Wimberger P, Lehmann N et al.. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).  Gynecol Oncol. 2007;  106 (1) 69-74
• 24 WMA The World Medical Association, France (2008) Declaration of Helsinki. http://www.wma.net/en/30publications/10policies/b3/index.html

Korrespondenzadresse